rodorubicin

structure given in first source

Also Known As:

cytorhodin S

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthacenes
        Anthracyclines: 9423
        rodorubicin: 4
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthacenes
    - Anthracyclines: 9423
      - rodorubicin: 4
Carbohydrates: 22023
- Glycosides: 2119
  - Aminoglycosides: 5131
    - Anthracyclines: 9423
      - rodorubicin: 4

Related Diseases

1.	Neoplasms (Cancer) 04/01/1989 - "Phase I studies of rodorubicin single bolus and daily times five, once every three weeks in patients with advanced solid tumors." 04/01/1988 - "Rodorubicin might be an interesting new candidate for further clinical evaluation and is the first drug being developed clinically in spite its inactivity in animal transplantation tumor systems." 04/01/1988 - "Rodorubicin is not active in the typical animal transplantation tumors and might therefore be a new leading structure with preferential activity against slow proliferating human tumors. " 04/01/1988 - "Rodorubicin is a new tetraglycosidic anthracycline, which was detected because of its activity against human tumors in a human tumor based screening system. "
2.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/01/1990 - "Rodorubicin was similarly attached to MoAb BW 575/931/2, directed against a small cell lung cancer associated antigen and to MoAb BW 431/26, recognizing an epitope detectable on carcinoembryonic antigen. "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 03/01/1990 - "The corresponding p-maleimidobenzoyl derivatives of beta-rhodomycin I, N,N-dimethyldaunorubicin, and rodorubicin have been attached to thiol groups of the hinge region of reduced monoclonal antibody BW 494/32, directed against a pancreatic cancer associated glycoprotein antigen, resulting in MoAb BW 494/32 conjugates, carrying 4.8-6.8 mol of cytotoxic residues/mol of MoAb. "
4.	Carcinoma (Carcinomatosis) 01/01/1989 - "Cytorhodin-S, an anthracycline derivative, was covalently coupled to a monoclonal antibody (mAb) CA208, against carcinoembryonic antigen (CEA) in order to achieve selective killing of a CEA-producing colon carcinoma cell line, COLO 205. "

Related Drugs and Biologics

1.	Anthracyclines
2.	Carcinoembryonic Antigen
3.	Monoclonal Antibodies
4.	Sulfhydryl Compounds (Thiols)
5.	Glycoproteins (Glycoprotein)
6.	Antigens
7.	Epitopes
8.	N,N-dimethyldaunorubicin
9.	rhodomycin

Related Therapies and Procedures

1.	Transplantation